Supera interwoven stent: optimal deployment for optimal durability

Lawrence A. Garcia, MD
Chief, Section Interventional Cardiology and Vascular Interventions
Director, Vascular Medicine
St. Elizabeth’s Medical Center
Tufts University School of Medicine
Boston, MA

Disclosure Statement of Financial Interest

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

<table>
<thead>
<tr>
<th>Affiliation/Financial Relationship</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grant/Research Support</td>
<td>iDev, Covidien/Medtronic</td>
</tr>
<tr>
<td>Consulting Fees/Honoraria</td>
<td>Covidien/Medtronic, Boston Scientific, Angiodynamics</td>
</tr>
<tr>
<td>Major Stock Shareholder/Equity</td>
<td>Arsenal, Primaxa, Transcend, CV Ingenuity, Scion Cardiovascular, Angio, Essential Medical</td>
</tr>
<tr>
<td>Royalty Income</td>
<td>None</td>
</tr>
<tr>
<td>Ownership/Founder</td>
<td>None</td>
</tr>
<tr>
<td>Intellectual Property Rights</td>
<td>None</td>
</tr>
<tr>
<td>Other Financial Benefit</td>
<td>None</td>
</tr>
</tbody>
</table>

Forces Exerted on the SFA

- Unfavorable anatomy
- Two bifurcations/articulations
- Unique vessel forces
- Diffuse disease
- High incidence of exclusive disease
- Extremity complex lesion morphologies
- Competitive flow via PFA

Shortcoming of SFA-Stents

- Stent Fracture
- Insufficient Radial Strength

Shortcoming of SFA-Stents

Insufficient radial strength in calcified lesions

Impaired primary patency due to residual stenosis

$P<0.05$
**Supera-Stent:**
*High Radial Force + Flexibility*

---

**CRUSH COMPRESSION DATA**

![Supera-stent (IDEV)]

---

**SUPERB Angiographic Analysis**

![Superb Angiographic Analysis](image)

**Outcomes in Severe Calcification**

![Outcomes in Severe Calcification](image)

**Deployment Technique Impact on 12-Month Patency**

![Deployment Technique Impact on 12-Month Patency](image)

**Freedom From TLR Across Lesion Lengths**

![Freedom From TLR Across Lesion Lengths](image)

**Deployment Technique Impact on Freedom From TLR**

![Deployment Technique Impact on Freedom From TLR](image)
Freedom From TLR Through 3 Years

Critical for Supera

- Predilation is critical for the best deployment
- Best deployment confers best outcomes both patency and lumen gain
- Focus on reference vessel and predilation must be 1:1 with this
- Use of 6.5 mm OD stent predilation best 6 or greater balloon

Images courtesy D. Schienert

Summary

- Supera has best in class SES outcomes at 1 year (KM estimate 86%)
  - Essentially 0 fracture rate
- TLR loss 7% over 3 years
- Best outcomes depends on optimal stent deployment
- Predilation remains the most critical portion in anticipation of stent deployment

SUPERA Stent 6 x 60 mm

Stented length 110 mm—nominal 60 mm—note overexpanded and contracted stented segment

Lesion visible in all images

Ruler visible

Stent perfectly deployed